Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 monoclonal antibody with zoledronic acid with or without denosumab for thyroid cancer bone metastases
ChiCTR2000037044Phase 4Recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of PD-1 Monoclonal Antibody, zoledronic acid and denosumab in thyroid cancer and bone metastases (2 arms), sponsored by Shanghai Sixth People's Hospital. Primary endpoints: Progression-free survival and Adverse events. Started Oct 2020; status: recruiting.
02
Drugs
PD-1 Monoclonal Antibodyzoledronic aciddenosumab
03
Conditions
thyroid cancerbone metastases
Beyond the preview
Go deeper on ChiCTR2000037044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037044.